Alterity Therapeutics (NASDAQ:ATHE) Lowered to Hold Rating by Benchmark

Alterity Therapeutics (NASDAQ:ATHE) was downgraded by stock analysts at Benchmark from a “speculative buy” rating to a “hold” rating in a report issued on Monday, MarketBeat.com reports.

Separately, Maxim Group upped their price objective on shares of Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th.

Alterity Therapeutics Price Performance

ATHE stock opened at $4.51 on Monday. The business has a 50 day simple moving average of $2.93 and a 200-day simple moving average of $1.87. Alterity Therapeutics has a twelve month low of $1.00 and a twelve month high of $5.87.

Institutional Trading of Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. HB Wealth Management LLC raised its holdings in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the period. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent reporting period. 2.14% of the stock is owned by hedge funds and other institutional investors.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.